MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2022.751296

Медицинская библиотека · Frontiers in immunology · 2022

Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect.

Huang Ying, Zou Yujing, Jiao Yiqun, Shi Peijie, Nie Xiaoli, Huang Wei, Xiong Chuanfeng, Choi Michael, Huang Charles, Macintyre Andrew N, Nichols Amanda, Li Fang, Li Chuan-Yuan, MacIver Nancie J, Cardona Diana M, Brennan Todd V, Li Zhiguo, Chao Nelson J, Rathmell Jeffrey C, Chen Benny J

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

Alloreactive donor T cells undergo extensive metabolic reprogramming to become activated and induce graft-versus-host disease (GVHD) upon alloantigen encounter. It is generally thought that glycolysis, which promotes T cell growth and clonal expansion, is employed in this process. However, conflicting data have been reported regarding the requirement of glycolysis to induce T cell-mediated GVHD due to the lack of T cell-specific treatments using glycolysis inhibitors. Importantly, previous studies have not evaluated whether graft-versus-leukemia (GVL) activity is preserved in donor T cells deficient for glycolysis. As a critical component affecting the clinical outcome, it is necessary to assess the anti-tumor activity following treatment with metabolic modulators in preclinical models. In the present study, we utilized T cells selectively deficient for glucose transporter 1 (Glut1T-KO), to examine the role of glycolysis exclusively in alloreactive T cells without off-targeting effects from antigen presenting cells and other cell types that are dependent on glycolysis. We demonstrated that transfer of Glut1T-KO T cells significantly improved acute GVHD outcomes through increased apoptotic rates, impaired expansion, and decreased proinflammatory cytokine production. In addition to impaired GVHD development, donor Glut1T-KO T cells mediated sufficient GVL activity to protect recipients from tumor development. A clinically relevant approach using donor T cells treated with a small molecule inhibitor of glycolysis, 2-Deoxy-D-glucose ex vivo, further demonstrated protection from tumor development. These findings indicate that treatment with glycolysis inhibitors prior to transplantation selectively eliminates alloreactive T cells, but spares non-alloreactive T cells including those that protect against tumor growth. The present study has established a definitive role for glycolysis in acute GVHD and demonstrated that acute GVHD can be selectively prevented through targeting glycolysis.

Для цитирования: Huang Ying, Zou Yujing, Jiao Yiqun, Shi Peijie, Nie Xiaoli, Huang Wei, Xiong Chuanfeng, Choi Michael, Huang Charles, Macintyre Andrew N, Nichols Amanda, Li Fang, Li Chuan-Yuan, MacIver Nancie J, Cardona Diana M, Brennan Todd V, Li Zhiguo, Chao Nelson J, Rathmell Jeffrey C, Chen Benny J. Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect.. Frontiers in immunology. 2022. DOI: 10.3389/fimmu.2022.751296.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.